Cognyte Software heads into the final quarter of 2026 with a muted price drift, a clean lending market, and a Street that remains split on whether the company's revenue mix problems are a temporary wobble or something deeper.
The lending market offers almost nothing of note here. Short interest amounts to under 1% of the free float, a genuinely low level that makes this one of the least-shorted names in its software peer group. Availability is effectively unlimited, running well above 9,000% of short interest, meaning there is far more stock available to borrow than anyone is trying to short. Borrowing costs have risen sharply in percentage terms, up 84% over the past month to 0.66%, but from such a low base that the absolute rate remains trivial. The short score sits at 27.9, and its ORTEX rank of 89 reflects how unusual it is for short sellers to have so little interest in a stock trading at $8.49 and down 3.5% over the past month. Options positioning has eased slightly, with the put/call ratio at 0.81, modestly below its 20-day average of 0.95. That is a mild softening of downside hedging demand rather than any directional conviction. The next earnings event is scheduled for December 10.
The Street is cautiously constructive but far from aligned. Two analysts carry buy ratings, one holds, and the consensus mean target of $12.33 implies roughly 45% upside from current levels. However, the most recent rating action was an initiation from Lake Street in early March 2026, at a $13 target, so fresh conviction has been limited in recent months. The bull case rests on surging cybersecurity demand, with disclosed vulnerabilities up 40% year-on-year and Cognyte's security analytics platform positioned to capture that tailwind. The bear case is harder to dismiss. Software revenue as a share of total revenue has slipped from 88.9% in FY24 to 85.9% in the first quarter of FY26. Recurring revenue dropped sequentially in that same quarter for the first time since mid-2024, falling to just 48% of total revenue. Valuation tells a mixed story: the PE multiple is tracking at 12.2x and has compressed by roughly 1.2 points over the past month, while EV/EBITDA of 6.6x has also ticked lower. The forward EPS revision cycle is the standout positive, with the 12-month forward EPS growth score registering at the 98th percentile of the ORTEX universe. Whether the earnings upgrade cycle survives the recurring revenue pressure is the core debate.
Institutional ownership adds some useful texture. Three holders sit at or near the 5% threshold as last disclosed. Edenbrook Capital held 9.8% as of June 30, adding 257,628 shares in the quarter. Topline Capital filed a 13G/A in February 2026 disclosing a 9.9% stake, and American Capital Management held 8.4% as of June 30 after trimming by 312,643 shares. None of these are Schedule 13D activist filings, so none carry an implied campaign mandate. Stakes disclosed under 13D/G rules are as-of-filing snapshots, and holders below 5% may exit without further disclosure. The combined picture is of a concentrated but essentially passive ownership base, which limits the catalyst risk in either direction.
Peers were broadly soft on the week. NOW fell 5.2% and AI dropped 4.7%, while AVPT and PD bucked the trend with modest gains. Cognyte's 1.6% weekly decline sits roughly in the middle of a disperse group, which is consistent with a stock lacking a near-term catalyst rather than one under active pressure.
What to watch into December 10 is whether recurring revenue stabilises as a share of the total, because that number more than any other will determine whether the analyst upgrade cycle holds or stalls.
See the live data behind this article on ORTEX.
Open CGNT on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
